JPRN-jRCT2080224962已完成1 期
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral Sclerosis
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
研究概览
简要总结
In 9 subjects with ALS, edaravone was well absorbed after oral administration with tmax of 0.08-0.50 hours. The mean Cmax and AUC0-inf of unchanged edaravone after oral administration of 105 mg edaravone were 1903 ng/mL and 1736 ng*h/mL, respectively. The edaravone was mainly eliminated into urine as glucuronide conjugate and subdominantly as sulfate conjugate after oral administration. Edaravone of 105 mg oral suspension were well tolerated and there were no safety concerns in the results of this study.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •The key criteria are listed below.
- •1. Patients aged between 20 and 75 years at the time of informed consent
- •2. Japanese patients
- •3. Among patients with ALS, those 'Clinically definite ALS', 'Clinically probable ALS' or 'Clinically probable-laboratory-supported ALS' according to El Escorial Revised Airlie House criteria
- •4. Patients who can consent to contraception
- •5. Patients who have thoroughly understood the contents of the study and voluntarily provided written informed consent to participate in the study
排除标准
- •The key criteria are listed below.
- •1. Patients in whom the possibility could not be ruled out that the current symptoms were symptoms of a disease requiring differential diagnosis, such as cervical spondylosis and multifocal motor neuropathy
- •2. Patients undergoing treatment for malignancy
- •3. Patients who have presence of clinically significant liver, heart, or renal disease requiring hospitalization (except ALS) and infections requiring antibiotics. Patients who have a problem in general condition and are judged ineligible by the Investigator
- •4. Body mass index (BMI) of <18.0 or >30.0, or a body weight of <50 kg
- •5. Patients judged by the investigator (or subinvestigator) to be unsuitable for the study for any other reason
研究者
相似试验
已完成
1 期
Clinical Pharmacology Study of Oral Edaravone in ALS Patients with PEGAmyotrophic Lateral SclerosisJPRN-jRCT2080225036Mitsubishi Tanabe Pharma Corporation6
已完成
1 期
Clinical Pharmacology Study of Oral Edaravone in Amyotrophic Lateral Sclerosis Patients With GastrostomyJapanese Patients With ALSNCT04254913Shionogi6
已完成
1 期
Clinical Pharmacology Study of Oral Edaravone in Patients With Amyotrophic Lateral SclerosisJapanese Patients With ALSNCT04176224Shionogi9
已完成
1 期
Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)Healthy Adult SubjectsNCT05342597Shionogi16
已完成
1 期
Study of Oral Edaravone in Healthy Adult MalesHealthy Adult SubjectsNCT04481750Shionogi74